BioCardia Inc (OTCMKTS:BCDA) CEO Peter Altman updates Proactive's Christine Corrado on the biotech's upcoming presentations at three cardiovascular conferences this fall which will reveal additional data from its open-label, roll-in cohort of the ongoing Phase 3 CardiAMP™ Heart Failure Trial.
Two presentations are scheduled at the Transcatheter Cardiovascular Therapeutics conference in San Diego on September 24, An invited presentation is scheduled at the Texas Heart Institute International Cardiovascular Regenerative Medicine meeting on October 5. A third presentation is scheduled at the American Heart Association Scientific Sessions 2018 conference November 12.
"It's pretty exciting to have the broader cardiovascular community be very receptive to the data and excited to put it on the podium," says Altman.